

Elvio Grazioso Russi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7792774/publications.pdf>

Version: 2024-02-01

86
papers

2,395
citations

201674

27
h-index

223800

46
g-index

86
all docs

86
docs citations

86
times ranked

3883
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose prescription in SBRT for early-stage non-small cell lung cancer: are we all speaking the same language?. <i>Tumori</i> , 2021, 107, 030089162092942.	1.1	3
2	How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. <i>World Journal of Urology</i> , 2021, 39, 1445-1452.	2.2	0
3	Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Medical Oncology</i> , 2020, 37, 85.	2.5	11
4	Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach. <i>Cancer Reports</i> , 2020, 3, e1285.	1.4	4
5	Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC). <i>Oral Oncology</i> , 2020, 107, 104801.	1.5	3
6	Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 597-599.	0.8	127
7	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. <i>Radiotherapy and Oncology</i> , 2020, 147, 229-230.	0.6	9
8	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. <i>Dysphagia</i> , 2019, 34, 52-62.	1.8	9
9	Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies' agenda. <i>Tumori</i> , 2019, 105, 161-167.	1.1	2
10	Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 48-53.	0.9	26
11	<i>Lactobacillus brevis</i> CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study. <i>Anticancer Research</i> , 2019, 39, 1935-1942.	1.1	55
12	How I treat squamous ENT cancer. <i>ESMO Open</i> , 2019, 4, e000542.	4.5	4
13	The value of prostate-specific antigen monitoring during salvage radiotherapy: a retrospective study and systematic review with meta-analysis. <i>Journal of Radiation Oncology</i> , 2019, 8, 413-423.	0.7	2
14	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Reviews in Oncology/Hematology, 2019, 134, 104-119.	4.4	10
15	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Overlock Reviews in Oncology/Hematology, 2019, 134, 87-103.	4.4	7
16	A new standardized data collection system for interdisciplinary thyroid cancer management: Thyroid COBRA. <i>European Journal of Internal Medicine</i> , 2018, 53, 73-78.	2.2	29
17	Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy. <i>International Journal of Cardiology</i> , 2018, 255, 175-183.	1.7	57
18	A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 121-124.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Pros and Cons of the New Edition of TNM Classification of Head and Neck Squamous Cell Carcinoma. <i>Oncology</i> , 2018, 95, 202-210.	1.9	24
20	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 122.	2.4	24
21	Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT) Tj ETQq1 1 0.784314 rgBT / cyclophosphamide. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 47-52.	1.7	12
22	What is the role of postoperative re-irradiation in recurrent and second primary squamous cell cancer of head and neck? A literature review according to PICO criteria. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 20-30.	4.4	15
23	Hadrontherapy from the Italian Radiation Oncologist point of view: face the reality. The Italian Society of Oncological Radiotherapy (AIRO) survey. <i>Radiologia Medica</i> , 2017, 122, 140-145.	7.7	4
24	Comparison of swallowing dysfunction after three-dimensional conformal and intensity-modulated radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 877-889.	2.0	31
25	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 157-165.	2.4	0
26	Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. <i>European Urology Focus</i> , 2017, 3, 321-324.	3.1	15
27	Head and neck cancer: improving outcomes with a multidisciplinary approach. <i>Cancer Management and Research</i> , 2017, Volume 9, 363-371.	1.9	150
28	External Beam Radiotherapy in Thyroid Carcinoma: Clinical Review and Recommendations of the AIRO Radioterapia Metabolica Group. <i>Tumori</i> , 2017, 103, 114-123.	1.1	5
29	P16 Cutoff in Head and Neck Squamous Cell Carcinoma: Correlation between Tumor and Patient Characteristics and Outcome. <i>International Journal of Biological Markers</i> , 2016, 31, 44-52.	1.8	2
30	Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience. <i>Clinical and Experimental Otorhinolaryngology</i> , 2016, 9, 287-297.	2.1	118
31	Correlation of TP53 and MDM2 Genotypes and Clinical Outcome in Platinum-Treated Head and Neck Cancer Patients with More than 10 Years Follow-Up. <i>International Journal of Biological Markers</i> , 2016, 31, 183-192.	1.8	7
32	Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 407-415.	1.3	28
33	Extreme hypofractionation for early prostate cancer: Biology meets technology. <i>Cancer Treatment Reviews</i> , 2016, 50, 48-60.	7.7	40
34	E1 Detection as Prognosticator in Human Papillomavirus-Positive Head and Neck Cancers. <i>International Journal of Biological Markers</i> , 2016, 31, 163-172.	1.8	2
35	Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 100-106.	4.4	62
36	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 47-54.	4.4	51

#	ARTICLE	IF	CITATIONS
37	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements.. Critical Reviews in Oncology/Hematology, 2016, 100, 147-166.	4.4	112
38	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 97, 131-142.	4.4	82
39	Management of Oropharyngeal Mycosis in Head and Neck Cancer Occurring during (Chemo) Radiotherapy: An Italian Radio-Oncologist Survey. Tumori, 2015, 101, 312-317.	1.1	2
40	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 95, 191-213.	4.4	33
41	Facial basal cell carcinomas treated with hypo-fractionated radiotherapy: A retrospective analysis in 117 elderly patients. Journal of the American Academy of Dermatology, 2015, 73, 166-168.	1.2	12
42	A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Supportive Care in Cancer, 2015, 23, 2231-2244.	2.2	25
43	Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Investigational New Drugs, 2015, 33, 310-320.	2.6	34
44	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 167-182.	4.4	46
45	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 372-384.	4.4	95
46	Prognostic value of HPV detection with three primer sets in 255 Head-Neck cancers.. Journal of Clinical Oncology, 2015, 33, 6045-6045.	1.6	0
47	Facial Basal Cell Carcinomas in Elderly Frail Patients Treated with Low Total-dose Radiotherapy. Anticancer Research, 2015, 35, 4949-53.	1.1	15
48	An Incidental Finding of Mucinous Colon Cancer by 18F-Choline PET/CT Determining a Change in Clinical Management of a Patient with Recurrent Prostate Adenocarcinoma. Case Reports in Oncological Medicine, 2014, 2014, 1-4.	0.3	3
49	Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation. Mediators of Inflammation, 2014, 2014, 1-14.	3.0	48
50	State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013. Oncology, 2014, 86, 212-229.	1.9	61
51	Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group. Radiation Oncology, 2014, 9, 264.	2.7	84
52	Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e1-30.e7.	1.6	6
53	Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. Supportive Care in Cancer, 2014, 22, 1889-96.	2.2	23
54	A systematic review of current and emerging approaches in the field of larynx preservation. Radiotherapy and Oncology, 2014, 110, 16-24.	0.6	47

#	ARTICLE	IF	CITATIONS
55	Contouring of the Pharyngeal Superior Constrictor Muscle (PSCM). A cooperative study of the Italian Association of Radiation Oncology (AIRO) Head and Neck Group. <i>Radiotherapy and Oncology</i> , 2014, 112, 337-342.	0.6	16
56	Abstract 1876: Combination of PI3KCA targeting with irradiation: A preclinical study on head and neck cancer cell lines. , 2014, , .		0
57	Role of IL-8 induced angiogenesis in uveal melanoma. <i>Investigational New Drugs</i> , 2013, 31, 1107-1114.	2.6	32
58	Strategies for Non-Resectable Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 492-504.	3.0	12
59	Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study. <i>Investigational New Drugs</i> , 2013, 31, 59-65.	2.6	15
60	Nonsurgical Conservative Approach for Laryngeal Cancer: What Information Should Patients Be Given?. <i>Journal of Clinical Oncology</i> , 2013, 31, 3168-3170.	1.6	4
61	Management of 'In-Field' Skin Toxicity in Head and Neck Cancer Patients Treated with Combined Cetuximab and Radiotherapy. <i>Oncology</i> , 2013, 85, 257-261.	1.9	11
62	A new approach for the pixel map sensitivity (PMS) evaluation of an electronic portal imaging device (EPID). <i>Journal of Applied Clinical Medical Physics</i> , 2013, 14, 234-250.	1.9	9
63	Dysphagia in Head and Neck Cancer Patients: Pretreatment Evaluation, Predictive Factors, and Assessment during Radio-Chemotherapy, Recommendations. <i>Clinical and Experimental Otorhinolaryngology</i> , 2013, 6, 117.	2.1	106
64	The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 2141-2147.	2.2	7
65	Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: Review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. <i>Cancer Treatment Reviews</i> , 2012, 38, 1033-1049.	7.7	106
66	Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 1051-1057.	1.5	44
67	MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 602-607.	1.5	9
68	Postoperative Therapy in Head and Neck Cancer: State of the Art, Risk Subset, Prognosis and Unsolved Questions. <i>Oncology</i> , 2011, 81, 21-29.	1.9	23
69	Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score. <i>Supportive Care in Cancer</i> , 2011, 19, 1823-1830.	2.2	21
70	Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. <i>Radiation Oncology</i> , 2011, 6, 162.	2.7	10
71	Cetuximab-Related Radiation Dermatitis in Head-and-Neck Cancer Patients: In Regard to Studer et Al. (Int J ETQq1 1 0.784314 rgBT 79, 1278.	0.8	2
72	Radiotherapy in Pleural Malignant Mesothelioma: Why not! in Regard to Scorsetti et al. (Int J Radiat Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 International Journal of Radiation Oncology Biology Physics, 2011, 79, 1279.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. <i>Oncologist</i> , 2011, 16, 228-238.	3.7	94
74	Epidermal growth factor receptor-inhibitors and radiotherapy-induced cutaneous adverse effects: the Koebner-Phenomenon or radio-dermatitis?. <i>Radiotherapy and Oncology</i> , 2009, 92, 142-143.	0.6	7
75	The cisplatin-irradiation combination suggests that apoptosis is not a major determinant of clonogenic death. <i>Anti-Cancer Drugs</i> , 2007, 18, 659-667.	1.4	8
76	Ultrathin Hydrocolloid Dressing in Skin Damaged From Alternating Radiotherapy and Chemotherapy Plus Cetuximab in Advanced Head and Neck Cancer (G.O.N.O. AlteRCC Italian Trial): In Regard to Macmillan et al. (<i>Int J Radiat Oncol Biol Phys</i> 2007;68:864-872). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 638-639.	0.8	12
77	Consideration about axillary nodes and arm position. <i>Radiotherapy and Oncology</i> , 2006, 79, 352-353.	0.6	0
78	Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 25-32.	0.8	24
79	Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: A pharmacology-guided schedule. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 731-737.	0.8	15
80	Adjuvant malignant mesothelioma radiotherapy: How many difficulties! In regard to: Allen et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma (<i>Int J Radiat Oncol Biol Phys</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 447 T pleurectomy/decortication for malignant pleural mesothelioma (<i>Int J Radiat Oncol Biol Phys</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 447 T	0.8	0
81	Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck. A phase II trial. <i>Radiotherapy and Oncology</i> , 2005, 75, 193-196.	0.6	14
82	Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions. <i>Lung Cancer</i> , 2002, 37, 201-206.	2.0	30
83	External radiation therapy boost to the vaginal vault: feasibility of intracavitary dosimetry using a commercial diode system. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 221-226.	0.8	2
84	Palliative-radiotherapy in lumbosacral carcinomatous neuropathy. <i>Radiotherapy and Oncology</i> , 1993, 26, 172-173.	0.6	10
85	Unusual relapse of hepatocellular carcinoma. <i>Cancer</i> , 1992, 70, 1483-1487.	4.1	51
86	Effect of Whole Brain Radiation on Local Cerebral Glucose Utilization in the Rat. <i>Neurosurgery</i> , 1991, 28, 491-495.	1.1	25